Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
U.S. Raises Alarm Over Chinese AI Firms’ Alleged IP Theft Through Model Distillation 
Why Global Web3 Projects Can't Afford to Skip South Korea: TokenPost Unveils Data-Driven Entry Solutions 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
Meta Expands AI Training With Employee Activity Tracking Tools 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations 
DeepSeek Launches V4 AI Models with Enhanced Reasoning and 1M Token Context Window 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
BRISBANE, Calif., May 19, 2017 -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced that it will release preliminary financial results for the first quarter 2017 after the market closes on Monday, May 22, 2017. Peter Maag, Chief Executive Officer, and Michael Bell, Chief Financial Officer, will host a conference call to review the Company’s results beginning at 1:30pm PT/4:30pm ET.
Individuals interested in listening to the conference call may do so by dialing (855) 420-0616 for domestic callers or (678) 304-6848 for international callers. Please reference Conference ID: 18923938. To listen to a live webcast, please visit the investor relations section of CareDx's website at: www.CareDx.com.
A replay of the call will be available beginning May 22, 2017 at 4:30 pm PT/7:30 pm ET through 4:30 pm PT/7:30 pm ET on May 23, 2017. To access the replay, dial (855) 859-2056 or (404) 537-3406 and reference Conference ID: 18923938. The webcast will also be available on CareDx's website for one year following the completion of the call.
About CareDx
CareDx, Inc., headquartered in Brisbane, California, is a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value solutions for transplant recipients. CareDx offers products across the transplant testing continuum, including AlloMap® and AlloSure™ for post-transplant surveillance and Olerup SSP®, Olerup QTYPE®,and Olerup SBT Resolver™ for pre-transplant HLA testing.
For more information, please visit: www.CareDx.com.
Investor Contact Caroline Corner, Managing Director Westwicke Partners, LLC T: +1 415-202-5678 E: [email protected]
